Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Le Cesne

Showing results (11-20 of 317) with videos related to

Pageof 32
Sort By:
Immunotherapy|September 9, 2025
Cracking the code: the emerging role of immune checkpoint inhibitors in PEComasTarek Assi, Axel Le Cesne
Future Oncology (London, England)|June 5, 2015
Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practiceAxel Le Cesne, Peter Reichardt
Targeted Oncology|April 4, 2009
Imatinib in the treatment of solid tumoursFlorence Duffaud, Axel Le Cesne
Future Oncology (London, England)|May 17, 2018
Quality of life and patients' expectations in soft tissue sarcomaRobin L Jones, Axel Le Cesne
The Oncologist|October 8, 2009
Adjuvant chemotherapy in localized soft tissue sarcomas: still not provenJean-Yves Blay, Axel Le Cesne
Cancer Treatment Reviews|August 17, 2011
A role for maintenance therapy in managing sarcomaIsabelle Ray-Coquard, Axel Le Cesne
Bulletin Du Cancer|June 3, 2004
[Docetaxel and non-small cell lung cancer]Yannick Le Guen, Axel Le Cesne
Bulletin De L'Academie Nationale De Medecine|April 5, 2013
[Medical therapy of GIST; from palliative to curative treatment]Axel Le Cesne, Jean-Yves Blay
Immunotherapy|March 31, 2025
Exploring the role of immune checkpoint inhibitors in solitary fibrous tumorsTarek Assi, Tania Moussa, Axel Le Cesne
Immunotherapy|December 9, 2020
Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?Tarek Assi, Axel Le Cesne, Olivier Mir
Pageof 32

Showing results (11-20 of 317) with videos related to

Sort By:
Pageof 32
Immunotherapy|September 9, 2025
Cracking the code: the emerging role of immune checkpoint inhibitors in PEComasTarek Assi, Axel Le Cesne
Future Oncology (London, England)|June 5, 2015
Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practiceAxel Le Cesne, Peter Reichardt
Targeted Oncology|April 4, 2009
Imatinib in the treatment of solid tumoursFlorence Duffaud, Axel Le Cesne
Future Oncology (London, England)|May 17, 2018
Quality of life and patients' expectations in soft tissue sarcomaRobin L Jones, Axel Le Cesne
The Oncologist|October 8, 2009
Adjuvant chemotherapy in localized soft tissue sarcomas: still not provenJean-Yves Blay, Axel Le Cesne
Cancer Treatment Reviews|August 17, 2011
A role for maintenance therapy in managing sarcomaIsabelle Ray-Coquard, Axel Le Cesne
Bulletin Du Cancer|June 3, 2004
[Docetaxel and non-small cell lung cancer]Yannick Le Guen, Axel Le Cesne
Bulletin De L'Academie Nationale De Medecine|April 5, 2013
[Medical therapy of GIST; from palliative to curative treatment]Axel Le Cesne, Jean-Yves Blay
Immunotherapy|March 31, 2025
Exploring the role of immune checkpoint inhibitors in solitary fibrous tumorsTarek Assi, Tania Moussa, Axel Le Cesne
Immunotherapy|December 9, 2020
Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?Tarek Assi, Axel Le Cesne, Olivier Mir
Pageof 32